deltatrials
Completed PHASE2 NCT00882999

A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis

Sponsor: Eli Lilly and Company

Conditions Relapsing-Remitting Multiple Sclerosis
Interventions LY2127399 Placebo
Updated 8 times since 2017 Last updated: Nov 10, 2018 Started: Apr 30, 2009 Primary completion: Feb 28, 2011 Completion: Jun 30, 2012

This PHASE2 trial investigates Relapsing-Remitting Multiple Sclerosis and is currently completed. Eli Lilly and Company leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Dec 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Belgrade, Serbia, Berlin, Germany, Biddeford, United States, Bratislava, Slovakia, Brno, Czechia, Budapest, Hungary, Caen, France, Charlotte, United States, Denver, United States and 53 more location s